Vaccines Market, By Type (Monovalent Vaccines , Multitvalent Vaccines), By Technology (Conjugate Vaccines, Recombinant Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Other Vaccine Technologies), By Disease Indication (Pneumococcal Disease, Influenza, Combination Vaccines, HPV, Meningococcal Disease, Herpes Zoster, Rotavirus, MMR, Varicella, Hepatitis, DTP, Polio, RSV, Other Disease Indications), By Route of Administration (Intramuscular, Subcutaneous, Oral, Intranasal), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Aug 2024

Code : CMI4914

Pages :165

Formats :

Excel and PDF

Industry : Biotechnology

Market Concentration and Competitive Landscape

Vaccines Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Increasing investments by pharmaceutical companies for vaccine development

Pharmaceutical companies have recognized lucrative opportunities in the vaccines market, considering its steady rise driven by the above factors as well as others. This has motivated them to increase investment in vaccine R&D, as well as expansion activities to capitalize on the market’s potential. Vaccine production requires sophisticated technology and facilities due to the delicate nature of live attenuated and subunit vaccine components. It also necessitates extensive clinical trials to ensure efficacy and safety. Meeting these challenges demands heavy investment, which companies are willing to undertake seeing the vaccines business as a long-term proposition. They have been channelling greater budgets into new vaccine R&D focusing on both pediatric as well as adult diseases. This has already resulted in vaccines for HPV, Hepatitis B, pneumonia, etc. to enter the market.

Besides R&D spending, companies are expanding manufacturing plants and enhancing their production capacities. Many have set up or are setting up new facilities especially in high-growth vaccine markets like Asia and Africa. This is to reduce transportation costs as well as address local regulations. Companies are also making strategic acquisitions that boost their vaccine portfolios and market reach as well. For instance, Merck’s acquisition of Themis and GSK’s acquisition of Novartis Vaccines business. Furthermore, innovative financing and partnership models have come up, with GAVI acting as a major advocacy and funding agency. This has bolstered pharmaceuticals companies’ confidence in their investments, as viable business models and market readiness get demonstrated. Strong economic incentives encourage ongoing contributions to the vaccine portfolio, thereby strengthening public health protection. Thus, increased investments by major pharmaceutical companies have accelerated vaccine supply and development of novel vaccines.

Key Players Insights